Sean I. Savitz, Edgar A. Samaniego, David S. Liebeskind, Johannes Boltze, Opeolu Adeoye, Joseph P. Broderick, Bruce Campbell, Davide Carone, Urs Fischer, Marc Fisher, Supurna Ghosh, George Harston, Michael D. Hill, Gary Houser, Pooja Khatri, William S. Korinek, Theodore E. Liston, Liping Liu, Patrick D. Lyden, Carolina M. Maier, Johanna M. Ospel, Marcelo Borges Rocha, Lee H. Schwamm, Kevin N. Sheth, Jocelyn Sutherland, Paul Wechsler
A STAIR XIII (Stroke Treatment Academic Industry Roundtable) workshop was held to discuss aspects of trials likely to have the greatest impact on detecting meaningful treatment effects of cerebroprotection in acute stroke. Intended goals for hyperacute protection should be focused on preserving penumbral tissue and delaying infarct core growth to augment the impact of reperfusion therapies. Infarct volume is a biologically and clinically meaningful surrogate imaging marker to assess the treatment effects of cerebroprotection. Lastly, clinical outcome measures for cerebroprotection should include domain-specific and patient-centered outcomes to detect clinically meaningful changes across multiple functional domains.